Home
Kieran Lamb's Library tagged → View Popular
The Big Question: Is depression increasing, and what is the best way to treat it? - The Independent 29th October 2009
"Why are we asking this now?
The National Institute for Clinical Excellence (Nice) yesterday published updated guidelines on the treatment of depression calling for extra focus on talking therapy, especially cognitive behaviour therapy, for depression and less focus on drugs. It also warned GPs to be more alert to depression in people with chronic health problems, amongst whom the condition is three times more common than in the general population. "
Millions with chronic illnesses 'should be checked for signs of depression' - Daily Telegraph 28th October 2009
"Millions of patients with chronic illnesses should be checked for signs of depression, a Government watchdog has recommended. "
Patients with cancer to be assessed for depression - The Guardian 28th October 2009
"GPs must assess people with chronic diseases to see whether they are suffering from depression, under new guidelines"
'Talk therapy' for the depressed - BBC Health News 28th October 2009
"Antidepressants should not be used routinely to treat depression in adults with chronic health problems, according to the treatment regulator, NICE.
Depression is two to three times more common in patients with problems such as cancer, heart disease and diabetes. "
Women denied cancer drug that could extend life - The Guardian 21st October 2009
"The National Institute for Health and Clinical Excellence proposes to reject a breast cancer drug despite its own rule changes on end-of-life treatments"
The thorny politics of NHS drug approval - The Guardian 21st October 2009
"The National Institute for Health and Clinical Excellence (Nice) is admired by governments abroad but regularly provokes an outcry in the UK. It was devised to do a job no health minister wants to do – to decide which new medicines are worth having in the NHS and which are too expensive.
The drug companies have been understandably hostile from the outset. More difficult for Nice has been the fury of patients' groups, which have sometimes gone into battle on the manufacturers' behalf."
Cancer drugs case study: 'I thought I had a year at most … the difference is huge' - The Guardian 21st October 2009
"Jo Waters, 55, was diagnosed with breast cancer in 2002.
"I had a mastectomy, chemotherapy and radiotherapy," she said. Then she had six cycles of Herceptin. It appeared to work. "I had two years of remission."
NHS watchdog refuses to sanction life-extending cancer drug - The Times 22nd October 2009
"A drug that can extend the life of women with advanced breast cancer has been turned down for use in the NHS by the cost-effectiveness watchdog.
The National Institute for Health and Clinical Excellence (NICE) said it plans to block use of Tykerb (lapatinib) in the Health Service after a second review. The decision comes despite rule changes brought in to let people at the end of their lives have the chance of new and often expensive treatments. "
Thousands of breast cancer sufferers to be denied life extending drug - Daily Telegraph 21st October 2009
"Breast cancer sufferers at the end of their lives should be denied a new drug that could give them three extra months, the NHS rationing body has recommended. "
Breast cancer sufferers will be denied life-extending drug championed by Jane Tomlinson - Daily Mail 21st October 2009
"Thousands of patients with advanced breast cancer are to be denied a 'last chance' drug on the NHS.
The Government's rationing body said lapatinib is too expensive even though its makers will provide the first three months' treatment free of charge."
New rheumatoid arthritis drug may be denied to NHS patients - Daily Telegraph 8th October 2009
"A new "smart" drug that can ease the agony of patients with previously untreatable rheumatoid arthritis has launched amid fears it will not be made available on the NHS."
New drug Tocilizumab could help 40,000 rheumatoid arthritis sufferers - The Times 8th October 2009
"An alternative new drug for rheumatoid athritis may help to ease the painful symptoms of 40,000 patients who do not benefit from current medications.
Tocilizumab is the first new treatment for the condition to be developed for ten years, but to treat one patient will cost up to £9,300 a year, and it has yet to be approved for widespread use on the NHS. Five trials involving more than 4,000 patients have shown that the injected treatment can transform the lives of patients who cannot tolerate other therapies or no longer respond to them. "
Banned drug improves symptoms in arthritis patients: review - Daily Telegraph 7th October 2009
"A drug for rheumatoid arthritis that is not approved for use on the NHS significantly improves symptoms in patients, a comprehensive study has found. "
Prescription guidelines deprive women of osteoporosis drugs, doctors say - The Times 8th September 2009
Women with osteoporosis are missing out on the best drugs for managing their condition because strict prescribing rules are distorting medical priorities, senior doctors said yesterday.
The availability of a cheap, generic preventive treatment for the bone-thinning disorder is “stifling” the adoption of newer, more expensive drugs that are more appropriate for many patients and promoting bad medical practice, the British Science Festival in Guildford was told.
Row over access to bone therapies - BBC Health News 8th September 2009
Thousands of women in England and Wales could suffer broken bones each year because of a lack of treatment, according to a leading physician.
Professor David Reid, from University of Aberdeen, said postmenopausal women may find they they are denied access to effective osteoporosis drugs.
Restrictions on prescription of osteoporosis drugs 'defy belief', says leading doctor - Daily Mail 8th September 2009
Thousands of women are being denied better osteoporosis drugs because of unnecessarily restrictive Government guidelines, a doctor said last night.
Professor David Reid, an expert on brittle bones, said the rules are so stringent that GPs are often prevented from giving alternative treatments to those suffering side-effects from their pills.
Kidney cancer patients fail to win appeal for expensive drugs on the NHS - The Times 26th August 2009
Hundreds of patients with kidney cancer will continue to be denied expensive drugs which could prolong their lives, despite an appeal by patients’ groups.
The National Institute for Health and Clinical Excellence (NICE) has declined to recommend bevacizumab (Avastin), sorafenib (Nexavar) and temsirolimus (Torisel) as first-line treatment options for advanced kidney cancer or cancer that has spread about the body.
Sutent for kidney cancer approved on NHS but other drugs turned down - Daily Telegraph 26th August 2009
Kidney cancer drug Sutent has been approved for use on the NHS after previously being denied, but three others have been turned down by the medicines rationing body, Nice, it was announced.
Healthcare trusts 'not paying for Nice approved drugs' - The Telegraph 20th August 2009
Four in 10 local healthcare trusts are not funding medications which have been approved by the Government’s drugs rationing body, a new survey shows.
NHS refuses cancer drug cash – again - Carlisle News & Star 3rd June 2009
A WHITEHAVEN man has been denied NHS funding for a lifeline cancer drug for a second time.
In fact, £19,000 of Michael Kennett’s funding for the drug Avastin which has been paid for so far – has come from local people fundraising.
Selected Tags
Related Tags
Health (85)- News (85)
- Evidence Based Practice (81)
- UHN (78)
- Drug Therapy (71)
- Rationing (48)
- Financial Management (26)
- Daily (23)
- Telegraph (23)
- NHS (21)
- Ethics (18)
- Daily Mail (15)
- Cancer (15)
- Kidney Cancer (11)
- Jurisprudence (10)
- The Guardian (9)
- BBC Health News (9)
- Health Economics (9)
- Osteoporosis (9)
Sponsored Links
Top Contributors
Highlighter, Sticky notes, Tagging, Groups and Network: integrated suite dramatically boosting research productivity. Learn more »
Join Diigo